Skip to main content
Smart Investors Daily
PA

NASDAQ · PALI

Palisade Bio, Inc.

Healthcare · Biotechnology

$1.12

Down-$0.09 (-8.04%)

Updated Nov 17, 2026, 1:36 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
327.06M
P/E ratio
-1.46
Dividend yield
0.00%
52-week range
$1.08 – $2.86
Volume
1.46M
Avg. volume
8.34M

Price performance · PALI

PALI price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

PALI closed at $1.12 after 20 trading sessions, down 16.42% for the selected period.

Last close
$1.12
Period change
-16.42%
Period low
$1.12
Period high
$1.43
Daily close
View OHLC price history
PALI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$1.15$1.15$1.08$1.121.46M
Nov 12, 2026$1.16$1.175$1.13$1.14985.37K
Nov 11, 2026$1.11$1.185$1.11$1.172.97M
Nov 10, 2026$1.18$1.20$1.11$1.131.62M
Nov 9, 2026$1.16$1.23$1.145$1.191.41M
Nov 6, 2026$1.14$1.18$1.10$1.132.03M
Nov 5, 2026$1.22$1.225$1.10$1.162.6M
Nov 4, 2026$1.26$1.30$1.21$1.252.02M
Nov 3, 2026$1.14$1.245$1.13$1.2318.65M
Nov 2, 2026$1.20$1.20$1.08$1.123.07M
Oct 30, 2026$1.18$1.20$1.115$1.163.09M
Oct 29, 2026$1.20$1.25$1.15$1.193.51M
Oct 28, 2026$1.22$1.22$1.10$1.1915.12M
Oct 27, 2026$1.22$1.255$1.17$1.206.01M
Oct 26, 2026$1.33$1.35$1.21$1.231.7M
Oct 23, 2026$1.35$1.37$1.28$1.331.33M
Oct 22, 2026$1.38$1.41$1.349$1.351.11M
Oct 21, 2026$1.44$1.46$1.39$1.401.43M
Oct 20, 2026$1.39$1.48$1.335$1.432.82M
Oct 19, 2026$1.41$1.46$1.32$1.341.84M

Latest PALI news

The latest Smart Investors Daily articles mentioning PALI.

PALI research

Overview

Company profile and research snapshot.

Company profile

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.50
Implied upside
—
Analysts
—
PALI recent ratings
DateFirmRatingTarget
Nov 11, 2026Piper SandlerOverweight—
Nov 11, 2026HC Wainwright & Co.Buy—
Oct 13, 2026HC Wainwright & Co.Buy—
Oct 9, 2026Raymond JamesOutperform—
Sep 23, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs

First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027 New Clinical and Translational Data Presented at ACG and UEG Week 2026 Highlight PALI-2108's Targeted Profile$113.6 Million in Cash and Cash Equivalents as of September 30, 2026 Denver, CO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage

Benzinga · Nov 10, 2026

Palisade Bio Q3 EPS $(0.07) Misses $(0.06) Estimate

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 81.58 percent increase over losses of $(0.38) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.